Journal
JOURNAL OF CONTROLLED RELEASE
Volume 259, Issue -, Pages 176-186Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2016.12.011
Keywords
Mertansine; Prodrug; cRGD; Reduction-responsive; Targeted chemotherapy
Funding
- National Natural Science Foundation of China [NSFC 51373113, 51225302, 51633005]
- Natural Science Foundation of Jiangsu Province [BK20131166]
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Ask authors/readers for more resources
Antibody-maytansinoid conjugates (AMCs) have emerged as one of the most promising active targeting cancer therapeutics. Their clinical use is, however, challenged by their low drug content, poor stability, high cost and potential immune response. Here, we designed and developed robust, cRGD-functionalized, reduction-sensitive polymeric micellar mertansine (DM1) prodrug (cRGD-MMP) that showed targeted treatment of B16F10 melanoma-bearing C57BL/6 mice. cRGD-MMP was obtained with a superb drug content of similar to 40 wt.% and a small size of similar to 45 nm from poly(ethylene glycol)-b-(poly(trimethylene carbonate)-graft-SSDM1) (PEG-P(TMC-g-SSDM1)) and cRGD-functionalized PEG-P(TMC-g-SSDM1) copolymers. cRGD-MMP exhibited excellent stability in 10% fetal bovine serum and cell culture medium while fast swelling and markedly accelerated drug release under a reductive environment. Confocal microscopy, flow cytometry and MTT assays indicated receptor-mediated uptake and high antitumor effect of cRGD-MMP in alpha(v)beta(3) integrin over-expressing B16F10 melanoma cells. Notably, cRGD-MMP displayed a long elimination half-life of 5.25 h and 4-fold better maximum-tolerated dose than free DM1. The in vivo studies demonstrated that cRGD-MMP effectively inhibited B16F10 melanoma growth and greatly improved mice survival rate as compared to free DM1 and non-targeted MMP control. cRGD-MMP with superior stability, drug loading, and alpha(v)beta(3) targetability offers an attractive alternative to AMCs for malignant tumor therapy. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available